In the past years Galapagos was a very good choice for investors. The stock was the past 5 years with a return of 543 percent one of the larger outperformers of her peer group. Shares of the peer group delivered the past 5 years a gain of at around 237 percent. Other strong winning shares of the sector are Pharming , Assembly Biosciences and Catalyst Pharmaceutical Partners. Assembly Biosciences, Catalyst Pharmaceutical Partners and Pharming are some of the winning stocks in the sector.
Over the current book year the total revenue will be 238,63 million euros (consensus estimates). This is quite more than 2017's revenue of 155,92 million euros.
The analysts expect for 2018 a net loss of 124 million euros. According to most of the analysts the company will have a loss per share for this book year of 2,44 euros. Based on this the price/earnings-ratio is -37,8.
Analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies is a limited 0,5 percent.
Galapagos 's market value equals around 4,27 billion . The Galapagos stock was the past 12 months quite unstable. Since last November the stock is 10 percent higher. This year the stock price moved between 71 and 105 euro. Since 2008 the stock price is almost 2290 percent higher.
At 17.35 the stock trades 1,5 percent lower at 92,24 euros.
ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com
Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.